1. Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine
   Yanbin Pang et al, 2019, Oncology Letters CrossRef
2. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia
   Yaqiong Tang et al, 2018, Clinical and Applied Thrombosis/Hemostasis CrossRef
3. Absence of early platelet increment in healthy mice during decitabine treatment
   Juliane Baumann et al, 2022, Scientific Reports CrossRef
4. Decitabine improves platelet recovery by down-regulating IL-8 level in MDS/AML patients with thrombocytopenia
   Wenxia Zhang et al, 2019, Blood Cells, Molecules, and Diseases CrossRef
5. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome
   Giulia Falconi et al, 2019, Leukemia Research CrossRef
6. Decitabine prior to salvaged cord blood transplantation for acute myeloid leukaemia/myelodysplastic syndrome not in remission
   Wen Yao et al, 2020, Journal of Clinical Pharmacy and Therapeutics CrossRef
7. Primary Immune Thrombocytopenia: Novel Insights into Pathophysiology and Disease Management
   Anurag Singh et al, 2021, Journal of Clinical Medicine CrossRef
8. Distinct bone marrow morphologic features discriminate myelodysplastic syndromes patients with and without an early platelet response to decitabine
   Annette M. May et al, 2020, British Journal of Haematology CrossRef
9. Platelet Doubling After First Decitabine Cycle Predicts Response and Survival of Myelodysplastic Syndrome Patients
   Ping-fan Lu et al, 2022, Current Medical Science CrossRef